0001104659-24-070108.txt : 20240610 0001104659-24-070108.hdr.sgml : 20240610 20240610203011 ACCESSION NUMBER: 0001104659-24-070108 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xynos Konstantinos CENTRAL INDEX KEY: 0001956241 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 241034431 MAIL ADDRESS: STREET 1: C/O REPLIMUNE GROUP, INC. STREET 2: 500 UNICORN PARK DRIVE CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 tm2416882-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-06-07 0 0001737953 Replimune Group, Inc. REPL 0001956241 Xynos Konstantinos C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE, SUITE 303 WOBURN MA 01801 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-06-07 4 S 0 15881 7.50 D 117131 D The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof. /s/ Shawn Glidden, attorney-in-fact 2024-06-10